AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06087991 — intervention group
Intervention type: BEHAVIORAL
Intervention: Implementation of the BINDeR-Tx service model
Description: ED-initiated buprenorphine, discharge with naloxone, and warm-hand off referral for continued treatment for individuals with OUD. This is considered standard treatment at the University of Utah ED. In order to extend these services to rural hospitals this study will be assisting Castleview Hospital to establish a similar program.
Study NCT04055129 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: Observational. Data will be gathered and analyzed on ligament laxity, EMG, kinetics and kinematics during a landing and jumping activity
Study NCT05814562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Intervention
Description: The study utilizes a tailored telemetric intervention to improve adherence to medications. The telemetric intervention (administered via telephone, or interactive internet chat applications such as Zoom ©, FaceTime ® or Skype ®) will enable experienced therapists to address nonadherence from a remote location, using a structured, tailored approach that accommodates specific patient needs.
Study NCT06424301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeting NUDT21 siRNA drugs
Description: It is performed for intravitreal chemotherapy.
Study NCT05497908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block via lateral approach
Description: TAP block via lateral approach
Study NCT05497908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block via posterior approach
Description: TAP block via posterior approach
Study NCT06331208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: non-contrast chest CT
Description: patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
Study NCT06331208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis
Description: patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
Study NCT05116761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Description: Intravenous administration of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Study NCT05116761 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo Saline
Study NCT06331208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood
Description: patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
Study NCT06331208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: supine bike exercise during right heart catheterisation
Description: subgroup of HF subjects who undergo right heart catheterisation will perform short supine bike exercise during RHC
Study NCT06331208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ventilation/perfusion SPECT
Description: subgroup of HF subjects will undergo ventilation/perfusion SPECT
Study NCT05487170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNK05047
Description: RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).
Study NCT05166967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individual Antithymocyte globulin
Description: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
Study NCT05166967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithymocyte globulin
Description: A 10mg/kg total dose of antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (from day -5 to day -2). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
Study NCT05464628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
Study NCT05464628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC42
Description: Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
Study NCT05049902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Use according to the drug combination options selected by each center.
Study NCT05049902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Use according to the drug combination options selected by each center.
Study NCT05049902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Use according to the drug combination options selected by each center.
Study NCT06369571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10mg daily by mouth
Study NCT06369571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modification of dietary fat composition
Description: Replace 10% of saturated fat intake with polyunsaturated fat
Study NCT05580718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-CBT
Description: * Education Common reactions following MI and general lifestyle advice on e.g., physical activity. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation.~* Goal setting Identifying life areas impaired by MI-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Exposure therapy Exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms. Gradual exposure to avoided situations, activities and increase in physical activity.~* Relapse prevention Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle.
Study NCT05049902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Use according to the drug combination options selected by each center.
Study NCT05049902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: Use according to the drug combination options selected by each center.
Study NCT05049902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Use according to the drug combination options selected by each center.
Study NCT05049902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Use according to the drug combination options selected by each center.
Study NCT05049902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Use according to the drug combination options selected by each center.
Study NCT05049902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Use according to the drug combination options selected by each center.
Study NCT05813743 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3 dimensional ultrasound
Description: Detect the accuracy of 3D ultrasonography in prenatal detection of bladder wall involvement in abnormally invasive placenta (AIP) at 3rd trimester of pregnancy .
Study NCT05049902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Use according to the drug combination options selected by each center.
Study NCT05049902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Pectin
Description: Use according to the drug combination options selected by each center.
Study NCT05622591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELU001
Description: Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
Study NCT05049902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal Bismuth Pectin
Description: Use according to the drug combination options selected by each center.
Study NCT05049902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan fumarate
Description: Use according to the drug combination options selected by each center.
Study NCT05049902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan fumarate
Description: Use according to the drug combination options selected by each center.
Study NCT05352074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subtotal colectomy with cecal-rectal anastomosis
Description: The intervention involves, after a complete mobilization of the colon, a resection 2-3 cm distal to the ileocecal junction and at the upper part of the rectal ampulla; the cecum is then lowered into the pelvis, without any rotation, and an antiperistaltic cecorectal anastomosis is performed between the cecal fundus (after appendectomy) and the rectum, after introduction of a stapler through the cecal resection line. In the laparoscopic approach we use 5 trocars (trocar 1 periumbilical, trocars 2-3-4-5 drawing a 15-cm side square around trocar 1), using a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The cecal-rectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
Study NCT05352074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total colectomy with ileorectal anastomosis
Description: After a complete mobilization of the colon, a resection 2-3 cm proximal to the ileocecal junction is conducted. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The ileorectal anastomosis (end to end) is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
Study NCT06462768 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.
Study NCT05065099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online Treatment Recovery Assistance for Concussion in Kids (OnTRACK)
Description: Patients and families will be provided the smartphone app on their personal mobile phone (Android, iPhone) or provided with a phone if they do not own one. The patients will view educational videos on concussion management, input their daily exertional status and weekly symptom status upon receiving pre-programmed notification prompts on their phone. Healthcare Providers will monitor symptom recovery via an HCP dashboard and make management recommendations using evidence-based algorithms regarding symptom recovery status. School personnel will monitor progress via a dashboard and provide targeted supports, they may also view educational videos on concussion management. Opportunities for communication between the HCP, parent/patient and school will be provided by the app.
Study NCT05283291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directed Imagery Technique
Description: The sound recording will include a soothing light background music for approximately 30 minutes.~Imagination will be practiced, starting with the patient's focusing his/her attention on his/her breath, relaxation, and relaxation with the suggestions given in the recording with the accompaniment of relaxing music.
Study NCT06152211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choir
Description: A choir for older adults is a musical/singing ensemble composed of individuals aged 65 and above. The choir rehearsals are weekly, 2 hours each and the length of the intervention is 16 weeks total.
Study NCT06152211 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Music Listening
Description: A weekly collective music listening, 2 hours each for 16 weeks.
Study NCT06124846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CB-Abst
Description: incentivized, biochemically verified abstinence via contingency management
Study NCT06124846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CB-Mon
Description: monitoring with no required abstinence
Study NCT05281328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2029
Description: SC injection using a pre-filled pen
Study NCT05005546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga will be applied to mothers in the yoga group
Study NCT05005546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Description: Laughter Yoga will be applied to mothers in the yoga group
Study NCT05281328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injection using a pre-filled pen
Study NCT05281328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection using a pre-filled pen
Study NCT06537531 — intervention group
Intervention type: OTHER
Intervention: Compare VCI scale
Description: Compare VCI scale
Study NCT05217537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline Injection [Nuzyra]
Description: Single dose of 100 mg omadacycline IV in 100 mL of normal saline
Study NCT05217537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline Oral Tablet
Description: Single dose of 300 mg omadacycline PO (2 x 150 mg tablets)
Study NCT05983653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthrocentesis without PRP
Description: 150 ml arthrocentesis without PRP
Study NCT05983653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthrocentesis with PRP
Description: 150 ml arthrocentesis with PRP
Study NCT04379011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Escalating brivaracetam dose to 150 mg twice daily for 3 months
Study NCT04379011 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for 3 months
Study NCT04833166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMAC D-blade videolaryngoscope with full or partial glottic view
Description: Deliberate achieving full or partial glottic view on C MAC D-blade video laryngoscope and comparing time and ease of intubation with both arms
Study NCT04833166 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CMAC D-blade videolaryngoscope with full or partial glottic view
Description: Deliberate achieving full or partial glottic view on C MAC D-blade video laryngoscope and comparing time and ease of intubation with both arms
Study NCT06081166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obicetrapib
Description: obicetrapib 10 mg daily
Study NCT06081166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium
Description: Atorvastatin 80 mg
Study NCT06081166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin Calcium
Description: Rosuvastatin 40 mg
Study NCT06227780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Auditory Entrainment
Description: Alpha Brainwave Entrainment (AAE) stimulus: starts at high theta range (7-Hz) through high alpha (13-Hz) in 2 Hz steps on a 500 Hz sine carrier tone~Target frequency: 10 Hz~Delivery: headphones/speakers
Study NCT06227780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alpha Auditory Entrainment
Description: Alpha Brainwave Entrainment (AAE) stimulus: starts at high theta range (7-Hz) through high alpha (13-Hz) in 2 Hz steps on a 500 Hz sine carrier tone~Target frequency: 10 Hz~Delivery: headphones/speakers
Study NCT04294290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hCT-MSC infusion
Description: This is a single site, phase I, open-label, prospective study of one intravenous infusion of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in 12 toddlers 18 to 48 months of age with autism spectrum disorder (ASD).
Study NCT06227780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Sham stimulus: carrier tone alone~Target frequency: N/A~Delivery: headphones/speakers
Study NCT06227780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham stimulus: carrier tone alone~Target frequency: N/A~Delivery: headphones/speakers
Study NCT04863950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: For surgical cohort patients, lomustine will be initiated (C1D1) within 6 weeks of surgery as soon as patient is deemed by the investigator (or designee) to be recovered enough for chemotherapy. Initiation of lomustine must be initiated within 6 weeks. If patient cannot be safely initiated on lomustine within this timeframe then they will be replaced.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), lomustine will be initiated on C1D1.~For both cohorts, lomustine will be administered as 110 mg/m2 PO once every 6 weeks.
Study NCT04863950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine Hydrochloride
Description: For the surgical cohort, imipramine hydrochloride will be initiated within a minimum of 16 days to a maximum of 3 weeks prior to surgery. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day to attain a maximum dose of 200mg/day in 16 days.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), imipramine hydrochloride will be initiated on Cycle 1 Day 1. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day, if tolerated, to attain a maximum dose of 200mg/day in 16 days.
Study NCT06535906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio taping
Description: The 5 cm wide Kinesio tape (Kinesio® Tex Gold™, Albuquerque, NM) applied to the participants has the ability to stretch up to 140% of its original length. Moreover, it provides comfortable use for 3 to 5 days thanks to its latex-free, cotton, hypoallergenic and porous features. The skin will be cleaned with alcohol before applying Kinesio tape. To prevent muscle tension, the physiotherapist will apply the kinesio tape inhibition technique to the wrist flexor muscles with light tension (15-25% of the current tension) from the end point to the origin. We will use this inhibition technique to prevent muscle spasm. Kinesio taping will be applied immediately after exercise
Study NCT06535906 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo kinesio taping
Description: 5 cm wide and 0.5 mm thick I-shaped Kinesio tape (Kinesio Tex® Gold) will be used. The tape will be applied in a plus-shaped, tension-free and technical sitting position. Kinesio taping will be applied immediately after exercise
Study NCT06535906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual lymph drainage
Description: Participants will lie in a supine position with their knees bent. Manual lymphatic drainage will begin with abdominal lymph drainage followed by central lymph stimulation. Then, bilateral axillary lymph nodes will be stimulated and the fluid in the exercised arm will be directed to the axillary lymph nodes. While the patients are in the prone position, the axillary lymph nodes will be stimulated in the same way and each manual lymphatic drainage will be performed from the back to the axillary lymph node. Each treatment session will last approximately 30 minutes
Study NCT06535906 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo manual lymph drainage
Description: Participants will lie in a supine position with their knees bent. It will only be moved in a stroking style with hand contact from the fingers towards the armpit.
Study NCT04701268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Device: Hemiverse
Description: Implantation of the hemiverse shoulder prothesis
Study NCT04916847 — intervention group
Intervention type: OTHER
Intervention: blood collection
Description: Depending on the weight of the child, between 5ml and 15ml of blood will be collected during a blood test necessary for the conventional care of the patient. A second blood sample will be taken one year later. The volume of blood taken does not exceed the volume allowed by the guideline Ethical considerations for clinical trials of medicinal products conducted in the paediatric population.~We will analyse:~1. Specific antibody responses (IgM, IgG, and immunoglobulin A (IgA) anti SARS-Cov-2) by quantitative chemiluminescence analysis.~2. Protective neutralizing capacity of these antibodies (neutralizing antibodies against SARS-cOV-2) by neutralization test.~3. SARS-Cov-2 specific memory T cell responses by multiparametric flow cytometry in order to characterize their maturation, differentiation, senescence, activation, secretion of interleukin (cytokines 2) , IFN-g, TNF) or Interferon-gamma (IFN-g) ELISPOT assay.
Study NCT06205290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liso-cel
Description: Specified dose on specified days
Study NCT06205290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idelalisib
Description: Specified dose on specified days
Study NCT06205290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Specified dose on specified days